334 related articles for article (PubMed ID: 28079862)
21. Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
Whiting REH; Robinson Kick G; Ota-Kuroki J; Lim S; Castaner LJ; Jensen CA; Kowal J; Nguyen A; Corado C; O'Neill CA; Katz ML
Exp Eye Res; 2020 Sep; 198():108135. PubMed ID: 32634395
[TBL] [Abstract][Full Text] [Related]
22. Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease).
Sindelar M; Dyke JP; Deeb RS; Sondhi D; Kaminsky SM; Kosofsky BE; Ballon DJ; Crystal RG; Gross SS
Sci Rep; 2018 Oct; 8(1):15229. PubMed ID: 30323181
[TBL] [Abstract][Full Text] [Related]
23. Neurofilament light is a treatment-responsive biomarker in CLN2 disease.
Ru Y; Corado C; Soon RK; Melton AC; Harris A; Yu GK; Pryer N; Sinclair JR; Katz ML; Ajayi T; Jacoby D; Russell CB; Chandriani S
Ann Clin Transl Neurol; 2019 Dec; 6(12):2437-2447. PubMed ID: 31814335
[TBL] [Abstract][Full Text] [Related]
24. Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease).
Sun Y; Almomani R; Breedveld GJ; Santen GW; Aten E; Lefeber DJ; Hoff JI; Brusse E; Verheijen FW; Verdijk RM; Kriek M; Oostra B; Breuning MH; Losekoot M; den Dunnen JT; van de Warrenburg BP; Maat-Kievit AJ
Hum Mutat; 2013 May; 34(5):706-13. PubMed ID: 23418007
[TBL] [Abstract][Full Text] [Related]
25. A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis.
Sanders DN; Kanazono S; Wininger FA; Whiting RE; Flournoy CA; Coates JR; Castaner LJ; O'Brien DP; Katz ML
Genes Brain Behav; 2011 Oct; 10(7):798-804. PubMed ID: 21745338
[TBL] [Abstract][Full Text] [Related]
26. Intraventricular Cerliponase Alfa Treatment in a Patient with Advanced Neuronal Ceroid Lipofuscinosis Type 2.
Nakashima S; Hamada M; Kimura T; Tanifuji S; Takahashi A; Yashita D; Kakimoto Y; Matsukawa T; Ishiura H; Toda T
Intern Med; 2024 Jun; 63(12):1807-1812. PubMed ID: 37926545
[TBL] [Abstract][Full Text] [Related]
27. Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.
Cabrera-Salazar MA; Roskelley EM; Bu J; Hodges BL; Yew N; Dodge JC; Shihabuddin LS; Sohar I; Sleat DE; Scheule RK; Davidson BL; Cheng SH; Lobel P; Passini MA
Mol Ther; 2007 Oct; 15(10):1782-8. PubMed ID: 17637720
[TBL] [Abstract][Full Text] [Related]
28. Partial genetic suppression of a loss-of-function mutant of the neuronal ceroid lipofuscinosis-associated protease TPP1 in Dictyostelium discoideum.
Phillips JE; Gomer RH
Dis Model Mech; 2015 Feb; 8(2):147-56. PubMed ID: 25540127
[TBL] [Abstract][Full Text] [Related]
29. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
[TBL] [Abstract][Full Text] [Related]
30. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis.
Chang M; Cooper JD; Sleat DE; Cheng SH; Dodge JC; Passini MA; Lobel P; Davidson BL
Mol Ther; 2008 Apr; 16(4):649-56. PubMed ID: 18362923
[TBL] [Abstract][Full Text] [Related]
31. Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses.
Sima N; Li R; Huang W; Xu M; Beers J; Zou J; Titus S; Ottinger EA; Marugan JJ; Xie X; Zheng W
Orphanet J Rare Dis; 2018 Apr; 13(1):54. PubMed ID: 29631617
[TBL] [Abstract][Full Text] [Related]
32. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.
Kohan R; Carabelos MN; Xin W; Sims K; Guelbert N; Cismondi IA; Pons P; Alonso GI; Troncoso M; Witting S; Pearce DA; Dodelson de Kremer R; Oller-Ramírez AM; Noher de Halac I
Gene; 2013 Mar; 516(1):114-21. PubMed ID: 23266810
[TBL] [Abstract][Full Text] [Related]
33. An integrated strategy for the diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven Latin American patients.
Kohan R; Cismondi IA; Kremer RD; Muller VJ; Guelbert N; Anzolini VT; Fietz MJ; Ramírez AM; Halac IN
Clin Genet; 2009 Oct; 76(4):372-82. PubMed ID: 19793312
[TBL] [Abstract][Full Text] [Related]
34. A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis.
Wang YL; Zeng ZY; Song XW; Hao ZF; Shi YW; Tang B; Chen SQ; Gao MM; Di W; Long YS; Yi YH; Liao WP
Neurogenetics; 2011 Feb; 12(1):93-5. PubMed ID: 20820830
[No Abstract] [Full Text] [Related]
35. Intravitreal gene therapy preserves retinal function in a canine model of CLN2 neuronal ceroid lipofuscinosis.
Kick GR; Whiting REH; Ota-Kuroki J; Castaner LJ; Morgan-Jack B; Sabol JC; Meiman EJ; Ortiz F; Katz ML
Exp Eye Res; 2023 Jan; 226():109344. PubMed ID: 36509165
[TBL] [Abstract][Full Text] [Related]
36. Global Brain Transcriptome Analysis of a Tpp1 Neuronal Ceroid Lipofuscinoses Mouse Model.
Domowicz MS; Chan WC; Claudio-Vázquez P; Henry JG; Ware CB; Andrade J; Dawson G; Schwartz NB
ASN Neuro; 2019; 11():1759091419843393. PubMed ID: 31003587
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.
Chakrabarti S; Chandra S; Roy A; Dasarathi S; Kundu M; Pahan K
Neurobiol Dis; 2019 Jul; 127():362-373. PubMed ID: 30928643
[TBL] [Abstract][Full Text] [Related]
38. Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification.
Meng Y; Sohar I; Wang L; Sleat DE; Lobel P
PLoS One; 2012; 7(7):e40509. PubMed ID: 22792360
[TBL] [Abstract][Full Text] [Related]
39. Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis.
Nemtsova Y; Wiseman JA; El-Banna M; Lobel P; Sleat DE
PLoS One; 2018; 13(2):e0192286. PubMed ID: 29408933
[TBL] [Abstract][Full Text] [Related]
40. CLN2 disease resulting from a novel homozygous deep intronic splice variant in TPP1 discovered using long-read sequencing.
Steigerwald C; Borsuk J; Pappas J; Galey M; Scott A; Devaney JM; Miller DE; Abreu NJ
Mol Genet Metab; 2023 Dec; 140(4):107713. PubMed ID: 37922835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
